1Y Close · As of Aug 26, 2026
Aprogen Biologics operates in the Pharmaceuticals sector.
Legal name: Aprogen Biologics Inc.
In fiscal year 2025, Aprogen Biologics (003060) reported revenue of 73.2 billion KRW, up 8.7% from 67.4 billion KRW a year earlier.
Operating profit was -60.4 billion KRW and net income was -168.3 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 31.2 billion KRW, with a P/B of 0.11.
These figures can be verified in the DART filing (receipt no. 20260320000881).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 73.2B | -60.4B | -168.3B |
| 2024 | 67.4B | -52.8B | -105.0B |
| 2023 | 87.4B | -57.5B | -115.3B |
Recent Filings
Large Shareholding Report (General)
Semi-Annual Report (2026.06)
Large Shareholding Report (General)
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-21 | Large Shareholding Report (General) |
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-08-11 | Large Shareholding Report (General) |
| 2026-08-07 | Large Shareholding Report (General) |
| 2026-07-31 | Largest Shareholder Change Report |